The newly established B. Braun Miethke GmbH & Co. KG, based in Potsdam, is devoted to developing innovative implants for targeted drug delivery. Under the direction of Brandon Loudermilk, the company is expected to bring its first product in this field to the market within the next years.
In contrast to conventional, oral drug administration, where the drug passes through the entire body, implants for targeted drug delivery transport pharmaceuticals directly to the targeted location in the patient’s body. This allows for a significant dose reduction and therefore reduces undesirable side effects for the patients.
“With this formation we want to join forces of several B. Braun divisions and our long-standing partner Christoph Miethke in the sense of Sharing Expertise. This collaboration will help us develop innovative products that enable us to access new market segments”, explains Prof. Boris Hofmann, Senior Vice President of the B. Braun Innovation Hub and Digital Innovation at Aesculap.
About Christoph Miethke
Christoph Miethke is the founder and CEO of Christoph Miethke GmbH & Co. KG. For 25 years, the company based in Potsdam develops, produces and distributes neurosurgical innovative products for the treatment of hydrocephalus. In this area, Aesculap AG and Christoph Miethke GmbH & Co. KG have been partnering successfully for many years.
More information about Christoph Miethke can be found at www.miethke.com.